The Celluma, a biophotonic medical device, was approved for six separate indications-for-use, including the treatment of acne, muscle and joint pain, muscle and joint stiffness, muscle spasm, arthritis and compromised local blood circulation.
“Receiving FDA clearance for six separate indications-for-use is a major milestone for us in the development of our product portfolio and the growth of the company,” said Patrick Johnson , president and CEO for BioPhotas in the release. “Our goal in developing the Celluma was to create a safe, effective and convenient device that could be used in the home and in a professional medical setting, and to do that at a fraction of the cost of the competition. We believe we have accomplished that goal with a product that is proprietary in design and novel in clinical application for pain management and certain skin conditions.”
BioPhotas is headquartered in Tustin, Calif.
Related Articles on FDA Clearances:
Riverain Technologies Receives FDA Clearance for ClearRead +Confirm Software
Siesta Medical Receives Additional FDA Clearances for Encore Tongue Suspension System
Vertiflex Receives FDA Clearance of Two Additions to Technology Portfolio
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
